Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/07/2876808/0/en/Inmagene-Announces-Completion-of-Enrollment-in-Phase-2a-Trial-of-IMG-007-a-Nondepleting-and-Half-life-Extended-Anti-OX40-Monoclonal-Antibody-in-Patients-with-Alopecia-Areata.html
https://www.globenewswire.com/news-release/2024/05/06/2875880/0/en/Inmagene-Reports-Positive-Interim-Results-from-Phase-2a-Trial-of-IMG-007-a-Nondepleting-Anti-OX40-Monoclonal-Antibody-with-an-Extended-Half-life-for-the-Treatment-of-Atopic-Dermati.html
https://www.prnewswire.com/news-releases/inmagene-exercises-option-to-obtain-exclusive-worldwide-license-for-img-007-and-img-004-from-hutchmed-302051787.html
https://www.prnewswire.com/news-releases/inmagene-doses-first-patient-in-phase-2a-trial-of-img-007-an-anti-ox40-monoclonal-antibody-with-an-extended-half-life-for-the-treatment-of-alopecia-areata-301956087.html
https://www.prnewswire.com/news-releases/inmagene-announces-formation-of-celexor-bio-based-on-its-anti-ilt7-mab-with-enhanced-pdc-depletion-function-301934416.html
https://www.prnewswire.com/news-releases/inmagenes-anti-ox40-mab-demonstrated-an-extended-half-life-and-a-favorable-safety-profile-in-a-phase-i-study-301904386.html
https://www.prnewswire.com/news-releases/inmagenes-ox40-mab-with-an-extended-half-life-and-silenced-adcc-enters-poc-study-in-atopic-dermatitis-301901200.html
https://www.clinicaltrialsarena.com/news/inmagene-topline-data-img-004/
https://www.prnewswire.com/news-releases/inmagene-receives-ind-clearance-for-img-008-a-long-acting-il-36r-mab-301739146.html
https://www.prnewswire.com/news-releases/inmagene-and-hutchmed-announce-first-participants-in-global-phase-i-trial-of-img-007-301581096.html